Citadel Advisors
OBIO icon

Citadel Advisors’s Orchestra BioMed OBIO Stock Holding History

Citadel Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$242K Sell
56,191
-22,994
-29% -$94K ﹤0.01% 11616
2026
Q1 		$337K Buy
79,185
+49,010
+162% +$209K ﹤0.01% 10211
2025
Q4 		$125K Sell
30,175
-23,827
-44% -$96.1K ﹤0.01% 11463
2025
Q3 		$134K Buy
54,002
+4,561
+9% +$12.6K ﹤0.01% 11622
2025
Q2 		$133K Buy
49,441
+28,961
+141% +$84.5K ﹤0.01% 11074
2025
Q1 		$87.7K Buy
20,480
+8,201
+67% +$40.8K ﹤0.01% 11649
2024
Q4 		$49.1K Sell
12,279
-7,836
-39% -$42.1K ﹤0.01% 12408
2024
Q3 		$103K Buy
+20,115
New +$131K ﹤0.01% 11073
2024
Q1 		– Sell
-10,112
Closed -$92.3K – 15220
2023
Q4 		$92.3K Sell
10,112
-160,309
-94% -$1.09M ﹤0.01% 11030
2023
Q3 		$1.49M Hold
170,421
– – ﹤0.01% 5784
2023
Q2 		$1.19M Hold
170,421
– – ﹤0.01% 6097
2023
Q1 		$3.34M Sell
170,421
-37
-0% -$428 ﹤0.01% 4468
2022
Q4 		$1.7M Sell
170,458
-1,350
-0.8% -$13.4K ﹤0.01% 5775
2022
Q3 		$1.7M Sell
171,808
-79,160
-32% -$785K ﹤0.01% 5898
2022
Q2 		$2.5M Sell
250,968
-10,626
-4% -$106K ﹤0.01% 5106
2022
Q1 		$2.59M Sell
261,594
-1,687
-0.6% -$16.7K ﹤0.01% 5506
2021
Q4 		$2.63M Buy
263,281
+3,457
+1% +$34.1K ﹤0.01% 5600
2021
Q3 		$2.57M Buy
259,824
+4,385
+2% +$43.3K ﹤0.01% 5740
2021
Q2 		$2.6M Sell
255,439
-3,651
-1% -$37.8K ﹤0.01% 5933
2021
Q1 		$2.91M Buy
259,090
+9,090
+4% +$111K ﹤0.01% 5519
2020
Q4 		$3.2M Hold
250,000
– – ﹤0.01% 4489
2020
Q3 		$2.75M Buy
+250,000
New +$2.81M ﹤0.01% 4123

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Citadel Advisors's OBIO Position: Q2 2026 in Review

Citadel Advisors reduced its Orchestra BioMed (OBIO) stake by 29% in Q2 2026, selling an estimated $94K and leaving 56,191 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #11616.

Citadel Advisors first reported a position in OBIO in Q3 2020 and has held it in 22 quarters since. The position peaked at $3.34M in Q1 2023. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Citadel Advisors held 56,191 shares of Orchestra BioMed worth $242K as of Q2 2026.
  • Citadel Advisors sold 22,994 Orchestra BioMed shares in Q2 2026, an estimated $94K.
  • Orchestra BioMed made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11616 holding.
  • Citadel Advisors first reported a position in Orchestra BioMed in Q3 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Orchestra BioMed position peaked at $3.34M in Q1 2023.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.